002626 Xiamen Kingdomway Group
- 14.35
- -0.14-0.97%
Xiamen Kingdomway Group News
Express News | Xiamen Kingdomway Group is one of the main producers of vitamin D3.
Subsidiary of Xiamen Kingdomway Group (002626.SZ) obtained food production license.
Xiamen Kingdomway Group (002626.SZ) announced that its wholly-owned subsidiary, Inner Mongolia Kingdomway Pharmaceutical Co., Ltd. (hereinafter referred to as ...
Xiamen Kingdomway Group (002626.SZ): The company's production capacity of vitamin D3 is 1600 tons.
On June 25th, Gelonhui reported that Xiamen Kingdomway Group (002626.SZ) stated on the investor interaction platform that the company's vitamin D3 production capacity is 1600 tons (equivalent to 500,000 IU/g specifications). The revenue proportion of the company's vitamin D3 is relatively small, and the output does not meet the disclosure requirements.
Xiamen Kingdomway Group's Q1 2024 financial report: analysis of financial data and performance.
As a leading enterprise in health food and fodder additive, Xiamen Kingdomway Group (stock code: 002626) covers the whole industry chain layout from raw material supply to brand operation. Recently, the company released its Q1 2024 financial report. This article will conduct an in-depth analysis of the data on assets and liabilities, profit, and cash flow to explore the latest performance of the company. In terms of the balance sheet data, the total assets of Xiamen Kingdomway Group at the end of this period are 5.561 billion yuan, increased by 3.88% compared with the beginning of the period, showing the steady expansion in the scale of the company. Among them, the final balance of goodwill increased slightly to 487 million yuan, indicating that the company is
Doctor's Best Inc. Acquires Viactiv Brand
Headquarters will be Based in Tustin, Calif. TUSTIN, Calif., June 11, 2024 /PRNewswire/ -- Doctor's Best, one of the nation's leading marketers of nutritional supplements and a wholly-owned subsidiar
Express News | Xiamen Kingdomway Group: Recently received 1 patent certificate issued by the National Intellectual Property Office.
Xiamen Kingdomway Group (002626.SZ): NMN products account for a small proportion of the brand's global sales, with limited impact on the brand's global revenue.
On June 5th, Xiamen Kingdomway Group (002626.SZ) stated on the investor platform that they received a notice from the platform advising all brand merchants to take down products containing NMN. Prior to this, the company had also been adjusting its sales strategy. The company's brand covers various product series such as cardiovascular and cerebrovascular health, bone health, male and female health, comprehensive health, and more than 300 SKUs. NMN products account for a small proportion of the brand's global sales, and their impact on the brand's global revenue is limited. Currently, the brand's business is proceeding normally and in an orderly manner.
Express News | Xiamen Kingdomway Group: Its holding subsidiary DRB has completed the acquisition of 100% equity of Activ Nutritional, LLC.
Express News | "Anti-aging drugs" NMN banned in China? Multiple parties respond.
Express News | Jin Dawei responds to the NMN cross-border e-commerce online sales ban: if necessary, it will respond to the outside world that the company's NMN business has not met disclosure standards
[BT Financial Report Momentary Analysis] In-depth Analysis of Jin Dawei's 2023 Report: A Comprehensive Review of Financial Health
As a high-tech enterprise focusing on R&D, production and sales of health food (including health food ingredients and health food terminal products) and feed additives, Jin Dawei (stock code: 002626) has attracted market attention. The company's business is spread all over the world, mainly exports, covering the entire health food industry chain, including raw material supply, formulation production, brand operation and channel layout, showing the company's competitive advantage within the industry and the strategic vision of the global layout. Judging from the balance sheet, Jin Dawei's total assets fell slightly from 5.425 billion yuan at the beginning of the year to 5 at the end of the year
Jin Dawei (002626.SZ): 2023 equity distribution of 10 distributions of 2 yuan Equity Registration Date June 5
On May 28, Ge Longhui (002626.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 2.000000 in cash (tax included) to all shareholders for every 10 shares based on the company's current total share capital of 609,934,771 shares. The share registration date for this equity distribution is June 5, 2024, and the ex-dividend date is June 6, 2024.
Jin Dawei (002626.SZ): Using synthetic biotechnology, it has been used in large-scale production of products such as Coenzyme Q10, NMN, ARA, etc.
Gelonghui, May 20, 丨 Jin Dawei (002626.SZ) said on the investor interactive platform that the company has used synthetic biotechnology for large-scale production of products such as coenzyme Q10, NMN, NADH, vitamin K2, nattokinase, PQQ, SAMe, DHA, ARA, etc., and also uses synthetic biology to lay out new products, such as astaxanthin, inositol, calcium pantothenate, glutathione, etc. The company will also use synthetic biotechnology to lay out biosubstitutes, such as alloxone sugar, tag sugar, etc.
Kim Dawei (002626.SZ): In the future, synthetic biotechnology will be used to lay out biosaccharides
Gelonghui, May 16, 丨 Jin Dawei (002626.SZ) held a performance briefing on May 16, 2024 to discuss “What products are the synthetic biotechnology currently used in the company, and what new products does it plan to use synthetic biotechnology to develop in the future?” The company replied that the company has used synthetic biotechnology in the production of products such as coenzyme Q10, NMN, NADH, vitamin K2, natto kinase, PQQ, adenosylmethionine, DHA, ARA, etc., and also uses synthetic biology to lay out new products, such as astaxanthin, inositol, calcium pantothenate, etc. In the future, the company will use synthetic organisms
Jin Dawei (002626.SZ): A number of new raw materials have entered the preparation stage for industrial production
Gelonghui May 16 | Jin Dawei (002626.SZ) held a performance briefing on May 16, 2024 to discuss “What technical reserves does the company have in the field of synthetic biology?” The company replied that the company has strong technical reserves and accumulation in the field of synthetic biological product manufacturing, and that the company has mastered the five core technologies of synthetic biological green manufacturing, microbial fermentation, chemical synthesis, natural product extraction, and microcapsule technology. The company has established a large-scale biological enzyme bank platform with in vitro biosynthesis and in vivo biosynthesis research and development capabilities. The company has created industrial strains, intelligent control of fermentation processes, and product application development
Kim Dawei | Frequent mergers and acquisitions, poor market capitalization, synthetic organisms, vitamins, NMN, and health products. Who will save them from their difficult performance?
Can performance be reversed again?
Express News | Jin Dawei: Recently, we have received a total of 3 invention patent certificates issued by the State Intellectual Property Office
The synthetic biology concept rose and spread in the afternoon. Shengda Biotech pulled up and stopped, and Jin Dawei, Zhejiang Zhenyuan, and Hanyu Pharmaceutical assisted in the back row.
The synthetic biology concept rose and spread in the afternoon. Shengda Biotech pulled up and stopped, and Jin Dawei, Zhejiang Zhenyuan, and Hanyu Pharmaceutical assisted in the back row.
Jin Dawei (002626.SZ): Net profit of 707.938 million yuan in the first quarter decreased by 18.58% year-on-year
On April 29, Ge Longhui (002626.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 743 million yuan, down 5.99% year on year; net profit attributable to shareholders of listed companies was 707.938 million yuan, down 18.58% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 697.157 million yuan, down 15.35% year on year; basic earnings per share were 0.12 yuan.
Jin Dawei (002626.SZ): “A method for preparing nicotinamide adenine dinucleotide” obtained an invention patent
Gelonghui, April 11 | Jin Dawei (002626.SZ) announced that the company's holding subsidiary Jiangsu Chengxin Pharmaceutical Co., Ltd., the company and its wholly-owned subsidiary Inner Mongolia Jindaway Pharmaceutical Co., Ltd., and its wholly-owned subsidiary Jindaway Biotechnology (Jiangsu) Co., Ltd. recently each received an invention patent certificate issued by the State Intellectual Property Office, which is a preparation method for nicotinamide adenine dinucleotide.
Analysis
Price Target
No Data
